Cencora (COR) stock
Health Care · Health Care Distributors
Cencora (COR) is a Health Care Distributors company in the Health Care sector, headquartered in Conshohocken, Pennsylvania. As of October 23, 2026, COR closed at $331.00, a market capitalization of $63.16 billion, the 196th largest company in the S&P 500. Over the last twelve months it generated $332.77 billion in revenue (+5% year over year) and $4.06 billion in free cash flow. The stock trades at 24.6x trailing earnings and 16.7x forward earnings.
- 1-year total return: +1.5% (dividends reinvested)
- 5-year return: +23.3% a year
- 52-week range: $244.82 – $377.54
- Gross margin 4.0%, operating margin 1.4%
- Dividend yield: 0.73%, 3 straight years of increases
- FI Handbook report card: C across 10 metrics
- 25th largest of 60 Health Care stocks in the S&P 500
COR price chart
1Y price change: +0.7% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| COR | +6.0% | -1.4% | +1.5% | +21.6% | +23.3% | +18.7% | +17.8% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1995.
COR key statistics
- Market cap
- $63.2B
- #196 in S&P 500
- P/E (TTM)
- 24.6x
- Forward P/E
- 16.7x
- EPS (TTM)
- $13.47
- Revenue (TTM)
- $332.8B
- +5%
- Free cash flow
- $4.1B
- Gross margin
- 4.0%
- Operating margin
- 1.4%
- Return on equity
- 96.9%
- Dividend yield
- 0.73%
- 52-week range
- $244.82 – $377.54
- Beta
- 0.58
- Price / sales
- 0.2x
- EV / EBITDA
- 13.5x
- Debt / equity
- 4.47x
- Employees
- 47,000
COR report card
CTen fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth5.1%C
- Gross margin4.0%F
- Operating margin1.4%D
- FCF margin1.2%D
- Return on equity96.9%A
- Net debt / EBITDA2.1xD
- Forward P/E16.7xB
- PEG ratio0.6xA
- Shareholder yield1.4%D
- Share count change / yr-1.0%B
Cencora financials
Revenue went from $146.8B in fiscal 2016 to $321.3B in fiscal 2025, growing 9.1% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.8B | $153.1B | $167.9B | $179.6B | $189.9B | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| Gross profit | $4.3B | $4.5B | $4.6B | $5.1B | $5.2B | $6.9B | $8.3B | $9.0B | $9.9B | $11.5B |
| Operating income | $1.5B | $1.1B | $1.4B | $1.1B | -$5.1B | $2.4B | $2.4B | $2.3B | $2.2B | $2.6B |
| Net income | $1.4B | $364.5M | $1.7B | $855.4M | -$3.4B | $1.5B | $1.7B | $1.7B | $1.5B | $1.6B |
| EPS (diluted) | $6.32 | $1.64 | $7.53 | $4.04 | $-16.65 | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
| Free cash flow | $2.7B | $1.0B | $1.1B | $2.0B | $1.8B | $2.2B | $2.2B | $3.5B | $3.0B | $3.2B |
| Buybacks | $2.3B | $329.9M | $639.2M | $674.0M | $420.4M | $82.2M | $483.7M | $1.2B | $1.5B | $435.5M |
| Dividends paid | $288.5M | $320.3M | $333.0M | $339.0M | $343.6M | $366.6M | $391.7M | $398.8M | $416.2M | $437.1M |
| Diluted shares | 226.0M | 221.6M | 220.3M | 211.8M | 204.8M | 208.5M | 211.2M | 204.6M | 200.3M | 195.2M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into COR?
A reverse DCF asks what growth the current price requires. With an enterprise value of $74.8B and $4.1B of trailing free cash flow, Cencora needs to grow free cash flow about 8.5% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 11.8% a year over the last five years.
P/E ratio history
Current 41.6x vs. median 21.2x (10th–90th percentile 13.9x–51.9x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
COR dividend
- Dividend yield
- 0.73%
- Annual dividend
- $2.40
- Years of increases
- 3
- 5-yr dividend growth
- -19.3%
- per year
- Payout ratio
- 17%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
COR analyst price targets
12 analysts' average 12-month target is $369.08 (+12% vs. $331.00). Targets range from $330.00 to $400.00. 71% rate it a buy.
COR earnings
Next report: November 4, 2026. Cencora has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $84.8B (+5% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 5, 2026 | $4.34 | $4.48 | +3.2% |
| May 6, 2026 | $4.73 | $4.75 | +0.5% |
| Feb 4, 2026 | $4.04 | $4.08 | +1.0% |
| Nov 5, 2025 | $3.79 | $3.84 | +1.4% |
| Aug 6, 2025 | $3.84 | $4.00 | +4.2% |
| May 7, 2025 | $4.10 | $4.42 | +7.9% |
| Feb 5, 2025 | $3.52 | $3.73 | +6.0% |
| Nov 6, 2024 | $3.23 | $3.34 | +3.5% |
Stocks like COR
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 MCK McKesson | -1.14% | +27% | $116.7B | 26.8x | Compare |
 CAH Cardinal Health | -2.37% | +58% | $57.8B | 34.5x | Compare |
 HSIC Henry Schein | -1.21% | +34% | $9.5B | 24.8x | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
 MRK Merck & | -1.34% | +72% | $358.4B | 117.2x | Compare |
COR news
- Cencora's Q4 2026 Earnings: What to Expect · Oct 24, 2026
- Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology · Oct 21, 2026
- Cencora (COR): 3 Reasons We Love This Stock · Oct 16, 2026
- Is Cencora (COR) Undervalued Or Is Raised Guidance Already Priced In? · Oct 16, 2026
- Is American Oncology Network (AONC) Fully Valued Following Cencora's $2.4b Buyout Deal? · Oct 24, 2026
COR stock FAQ
What is COR's market cap?
Cencora's market capitalization is $63.16 billion as of October 23, 2026, ranking 196th in the S&P 500.
What is COR's P/E ratio?
COR trades at a trailing price-to-earnings ratio of 24.6x and a forward P/E of 16.7x. Its median P/E over the period we track is 21.2x.
Does COR pay a dividend?
Yes. Cencora pays $2.40 per share a year, a 0.73% yield. It has raised its dividend 3 years in a row. Dividends fell 19.3% a year over the last five years.
How much has COR stock returned?
Including reinvested dividends, COR returned +1.5% over one year, +23.3% a year over five years, +18.7% a year over ten years through October 23, 2026.
Is COR stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Cencora must grow free cash flow about 9% a year for the next decade. Its free cash flow grew 12% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the COR price target?
12 analysts cover COR with an average 12-month price target of $369.08, +12% from the current price. 71% of them rate it a buy.
When does COR report earnings?
Cencora is expected to report earnings on November 4, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Cencora have?
Cencora has about 47,000 full-time employees, or $7.1 million of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology